This list is incomplete; you can help by adding missing items. (March 2022)

This page is a list of EORTC clinical trials sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).

• EORTC 10085 – characterization of male breast cancer^[1][2]
• EORTC 10863 – continuous tamoxifen versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate^[3]
• EORTC 10951 – exemestane versus tamoxifen^[4]

• Nafoxidine versus ethinylestradiol^[5]
• Levodopa versus nafoxidine^[6]

The following prostate cancer trials have been conducted, among others:^[7][8]

• EORTC 30761 – cyproterone acetate 250 mg/day versus medroxyprogesterone acetate 200 mg/day versus diethylstilbestrol 3 mg/day^{[7][9][10][11][12]}
• EORTC 30762 – estramustine phosphate 280 mg/day (560 mg/day initially) versus diethylstilbestrol 3 mg/day^{[7][9][13][12]}
• EORTC 30805 – orchiectomy versus orchiectomy plus cyproterone acetate (150 mg/day) versus low-dose diethylstilbestrol (1 mg/day)^[14][15][16]
• EORTC 30843 – orchiectomy versus buserelin versus buserelin plus cyproterone acetate (150 mg/day)^[7][17][18]
• EORTC 30853 – orchiectomy versus goserelin plus flutamide (750 mg/day)^{[7][19][20][21]}
• EORTC 30892 – flutamide monotherapy (750 mg/day) versus cyproterone acetate (300 mg/day)^[22][23][24]
• EORTC 30903 – prednisone versus flutamide^[7]
• EORTC 30954 – intermittent combined androgen blockade (with GnRH agonist plus bicalutamide (50 mg/day))^[7][25][26]
• EORTC 30958 – intermittent combined androgen blockade^[27]